Seres Therapeutics stockholders approve incentive plan increase at reconvened annual meeting

Seres Therapeutics, Inc. disclosed in an 8-K that on July 8, 2026 it reconvened its 2026 Annual Meeting of Stockholders, which had been adjourned from June 9, 2026 due to a lack of quorum.¹ At the reconvened session, a total of 4,985,176 shares of common stock were represented in person or by proxy, representing approximately 51.75% of outstanding common stock as of the April 13, 2026 record date.¹

Stockholders elected three Class II directors to serve until the 2029 Annual Meeting: Stephen A. Berenson, Claire M. Fraser, Ph.D., and Richard N. Kender. Berenson received 3,690,033 votes for and 426,428 withheld; Fraser received 3,825,690 for and 290,771 withheld; and Kender received 3,824,452 for and 292,009 withheld, with 868,715 broker non-votes recorded for each nominee.¹

Shareholders also ratified PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for fiscal year 2026 and approved, on an advisory basis, executive compensation. They approved an amendment and restatement of the company's 2025 Incentive Award Plan to increase shares available for issuance by 900,000, with 3,438,763 votes for, 597,484 against, 80,214 abstained, and 868,715 broker non-votes.¹

The plan increase had already been approved by the company's Board of Directors on April 22, 2026, contingent on stockholder approval, which took effect once shareholders voted in favor at the Annual Meeting.¹ A related proposal sought authority to adjourn the meeting if more proxies were needed to pass the plan amendment; that adjournment proposal was also approved, though it proved unnecessary since Proposal 4 already had sufficient support.¹